K2B-lead-PDC

K2B-lead-PDC is an engineered SIRPα-based protein-drug conjugate (PDC) developed by K2B Therapeutics for the treatment of solid tumors. The drug is designed to target CD47, a transmembrane protein that acts as a "don't eat me" signal frequently overexpressed on cancer cells to evade phagocytosis. Unlike traditional anti-CD47 monoclonal antibodies, this PDC utilizes a modified SIRPα protein as the targeting moiety to deliver the cytotoxic payload monomethyl auristatin E (MMAE), a potent microtubule inhibitor. A key feature of the program is its "hit-and-run" pharmacology, which is intended to minimize the "sink effect" caused by CD47 expression on healthy red blood cells, thereby reducing the risk of hematologic toxicities such as anemia. The program was developed in partnership with the Korea Institute of Science and Technology (KIST) and is currently in preclinical stages.

Other names

K2B Therapeutics CD47 PDCK-2B Therapeutics CD47 PDCK 2B Therapeutics CD47 PDCSIRPα-MMAE conjugateunnamed lead program